Several groups have recently described the isolation of a 20 kDa membrane-attack-complex (MAC)-inhibiting protein, termed 'CD59 antigen', from human erythrocyte membranes. Antibodies raised against erythrocyte CD59 antigen detect antigen on the surface of many other cell types, and in some of these cells the antigen has been shown to have a molecular mass similar to that of the erythrocyte protein and to confer resistance to lysis by the MAC. A platelet-membrane form of CD59 antigen has been described and reported to be much larger than the erythrocyte protein. Here I report the isolation of CD59 antigen from platelet membranes and its molecular and functional characterization. The platelet protein is not significantly larger than the erythrocyte form and possesses similar MAC-inhibiting activity. Platelet CD59 antigen is anchored to the membrane via a glycosyl-phosphatidylinositol link, and consequently it is suggested that deficiency of this protein might be responsible for the increased thrombotic tendency observed in paroxysmal nocturnal haemoglobinuria.
INTRODUCTION
Within the past 5 years it has become clear that human cells express membrane proteins which confer resistance to lysis by the membrane attack complex (MAC) of homologous complement. At least two such proteins exist, a 70 kDa molecule termed 'homologous restriction factor ' (HRF; Zalman et al., 1986) , C8-binding protein (C8bp; Schonermark et al., 1986) or MAC-inhibiting protein (MIP; Watts et al., 1987 Watts et al., , 1990 ) and a 20 kDa protein, CD59 antigen, which possesses a bewildering array of alternative names (Sugita et al., 1988; Davies et al., 1989; Holguin et al., 1989; Okada et al., 1989) . CD59 antigen has been purified from erythrocyte membranes, and the purified protein, by virtue of its retention of an intact glycosylphosphatidylinositol (GPI) anchor, can be incorporated into the membranes of heterologous target cells or liposomes, rendering them resistant to lysis by the homologous MAC. The protein acts at the final stage of assembly of the MAC, incorporating into the complex, thereby preventing recruitment of multiple C9 molecules and subsequent pore expression (Meri et al., 1990 ; Rollins & Sims, 1990) . Specific antibodies raised to the cellassociated or purified protein have identified the presence of CD59 antigen on many cell types and in tissues (Hideshima et al., 1990; Nose et al., 1990; Sayama et al., 1990) . The molecular and functional characteristics of the protein have, however, been examined on only a few cells. Neutralization of CD59 antigen with antibody rendered human glomerular epithelial cells, amniotic epithelial cells and thyroid follicular cells more susceptible to lysis by the MAC (Rooney & Morgan, 1990; Rooney et al., 1991; Weetman & Morgan, 1991) and Western blotting of cell membranes demonstrated a band with a molecular mass similar to that of the erythrocyte protein. In contrast, anti-CD59
antibodies have been reported to recognize a 37 kDa protein in Western blots of platelet membranes, and neutralization of platelet CD59 antigen with antibody caused little enhancement of lysis (Sims et al., 1989) . Nevertheless, a functional role of platelet CD59 antigen was suggested by the observation that antibody neutralization enhanced MAC-induced platelet procoagulant activity.
The presence of a markedly different form of the CD59 antigen was intriguing, particularly in view of the similarity between the erythrocyte protein and that on diverse nucleated cell types. The purpose of the present study was therefore to isolate and characterize platelet CD59 antigen in order to elucidate the reasons for the reported differences.
MATERIALS AND METHODS Materials
Phosphate-buffered saline (0.01 M-sodium phosphate/0. 14 MNaCI), pH 7.4 (PBS) was supplied in tablet form by Oxoid Ltd. Alternative pathway buffer (APB) was Veronal-buffered saline (0.005 M-sodium Veronal/0.14 M-NaCI), pH 7.4, containing 0.007 M-MgSO4 and 0.01 M-EGTA. Phosphatidylinositol-specific phospholipase C (PI-PLC) was obtained from Fumakoshi Pharmaceutical Co. (Sapporo, Japan). All other chemicals were from Sigma (Poole, Dorset, U.K.) or from BDH (Poole, Dorset, U.K.) and were of the best grade available. Normal human serum (NHS) was obtained from volunteers and stored in aliquots at -70°C until use. Cobra venom factor (CVF) was purified from venom by published methods (Vogel & Muller-Eberhard, 1984 Leung et al., 1981; Tetteroo et al., 1983) Control cells were incubated without antibody. The cells were then washed and resuspended in APB (2 ml) containing 2 ,ug of CVF, divided into 100 portions, and triplicate portions were incubated withl0 ,u l of dilutions of NHS between 0 and 1:2 for 1 h at 37 'C. Intact cells and debris were removed by centrifugation and the lactate dehydrogenase (LDH) content of the supernatants measured by a micromodification of standard methods (Decker & Lohmann-Matthes, 1988 ).
Release of platelet CD59 antigen by P1-PLC Washed platelets in PBS (109/ml) were incubated in either the absence or presence of PI-PLC (2 ,ul/ml; about 0.1 unit) at 37°C for I h. The cells were then washed once and resuspended in PBS containing 100 BSA and 0.1°0/ NaN3 and incubated with BRIC-229 or DAKO-GpIIla (each at 1:10 final dilution of culture supernatant) for 30 min on ice. After washing twice in the above buffer the cells were incubated with rabbit anti-mouse IgG-FITC conjugate diluted 1:100 in the above buffer for 30 min on ice.
The cells were then washed and fixed in 2 00 paraformaldehyde before fluorescence-activated-cell-sorter (FACS) analysis. Analysis was performed on a FACS 440 instrument (BecktonDickinson). In some experiments, lymphocytes and erythrocytes were similarly PI-PLC-treated, stained and analysed on the FACS to provide evidence of the efficacy of the techniques used.
Purification of platelet CD59 antigen
Outdated platelet concentrate (25 packs; total vol. 1200 ml) was obtained from the blood bank at the University Hospital of Wales. Platelet concentrate contains at least 1.1 x 109 platelets/ml. The platelets were pooled and centrifuged at low speed (650 g in the GSA rotor of a Sorvall Superspeed centrifuge) for 20 min to pellet contaminating erythrocytes and leucocytes. The supernatant platelet-rich plasma was then spun at 24000 g to pellet platelets. Platelets were then resuspended in 500 ml of PBS, pelleted by centrifugation, and this wash step was repeated twice more. Contamination of the platelet preparation with erythrocytes and leucocytes was assessed by microscopic examination in a haemocytometer. At least ten separate fields of the suspension were counted. Erythrocyte contamination was less than 104/ml, and leucocyte contamination was less than 105/ml (platelet concentration 2.5 x 109/ml in this suspension).
The platelets were again pelleted (50 ml packed cell volume), resuspended in 200 ml of water and stirred for 30 min to lyse cells. Membranes were collected by centrifugation at 27000 g in the SS34 rotor for 30 min, washed once in PBS, suspended in 50 ml of PBS. containing 40 CHAPS and stirred overnight at 4 'C. Insoluble material was removed by centrifugation (27000 g in a SS34 rotor) for 30 min at 4 'C and the clear supernatant extensively dialysed against PBS containing 0.05 % CHAPS. The dialysed extract (total volume 90 ml) was tested for MACinhibitory activity as described below and then applied to an anti-CD59 immunoaffinity column (YTH53.1 immobilized on Sepharose 4B) equilibrated in PBS/0.05Qo CHAPS. After extensive washing in equilibration buffer and in equilibration buffer containing 0.5 M-NaCl, the bound protein was eluted using 0.02 M-diethylamine, pH 11.5, containing 0.05 % CHAPS.
Fractions (1 ml) were collected into Tris (1M, pH 7.0, 0.1 ml) to restore the pH value to neutrality. Eluted protein was dialysed against PBS/0.05 % CHAPS overnight and then concentrated to 4 ml in an Amicon ultrafiltration cell using a PM 10 membrane. The eluted protein was further purified by gel filtration on an f.p.l.c. system (Pharmacia) using a Superose 6 column equilibrated and run in PBS/0.05 %O CHAPS.
Assessment of MAC-inhibitory activity of isolated platelet CD59
Portions (1 ml) of GPE (5 v/v in PBS) were incubated with various amounts of dialysed platelet membrane extract or affinitypurified platelet CD59 antigen (all diluted to 0.1 ml in PBS/0.05 0 CHAPS) for 30 min at 37 'C. The cells were washed twice in APB and resuspended to 1 ml in APB containing CVF at 2,tg/ml. Portions (100 in triplicate) were then incubated with I00 ,ul of NHS at a final dilution of 1: 10, 1: 20 or 1: 40 for 30 min at 37 'C. Cells were centrifuged and the percentage haemolysis calculated from haemoglobin release into the supernatant by measuring absorbance at 540 nm in a Titertek Multiscan plate reader (Flow Laboratories, Paisley, Renfrewshire, Scotland, U.K.).
In one experiment, erythrocyte CD59 antigen (purified as described previously; Meri et al., 1990) Vol. 282 411 positive control antibody anti-GPIIIa and with the anti-CD59 antibody. The fluorescence with both antibodies was unimodal, but displayed considerable overlap with the negative controls (Fig. 3) . For GPIIIa, 69 % of the cells were positive with respect to the gate set using the negative control population, and the modal fluorescence was 105.6 units (modal fluorescence of controls 32 units). For CD59 antigen, 520% of the cells were positive with respect to the control gate and the modal fluorescence was 91.4 units. PI-PLC treatment caused a downward shift in the fluorescence pattern for CD59 antigen expression (27 % positive with respect to control gate; modal fluorescence 59.2 units), but did not alter the expression of GpIIIa (Fig. 3) .
Lymphocytes treated in an identical manner were 890 positive for CD59 antigen before incubation with PI-PLC, but only 190 positive afterwards, whereas erythrocyte expression was only slightly decreased (92 % before, 81 % after) (results not included).
Platelet membrane CD59 antigen was purified from solubilized membranes by immunoaffinity chromatography and gel filtration. A second passage of the solubilized membranes over the affinity column extracted no more protein, implying that all the available antigen bound in the first pass. The protein eluted from the Superose 6 column as a single peak with an apparent molecular mass of approx. 500 kDa, indicating that CD59 antigen was present as a detergent-protein complex. On SDS/PAGE the purified protein gave a single major band with an apparent molecular mass of between 18 and 20 kDa (Fig. lb) . Only this major band was detected by anti-CD59 antibody in Western blots of the purified protein (Fig. la) . The yield from two purifications was 85 ,tg and 65 ,tg respectively by a Coomassie Blue-based protein assay kit (Pierce).
MAC-inhibitory activity of platelet CD59 antigen
Incubation of GPE with solubilized dialysed platelet membranes or with purified platelet CD59 antigen rendered the cells resistant to subsequent lysis by the MAC. The purified antigen was much more active than the membrane extract, and the effects were dependent on the dose of antigen added to the cells, reaching a maximum at 1.5 ,ug/ml at the highest serum dose used (Fig. 4a) . At the lowest serum dose used, 50 % inhibition of GPE lysis was achieved by preincubation with purified antigen at 60 ng/ml, whereas a 1: 5 dilution of membrane extract (protein concn. approx. 100 ,tg/ml) was required to achieve this degree of inhibition.
The protective effect of preincubation with CD59 antigen or membrane extract could be neutralized by incubation ofprotected cells with anti-CD59 antibody (results not shown). Comparison of the protective effects of erythrocyte CD59 antigen, purified as described previously (Meri et al., 1990) , and platelet CD59 antigen on GPE revealed that the two proteins had similar inhibitory activities (Fig. 4b) .
DISCUSSION
The first aim of the present study was to characterize the 38 kDa variant of CD59 antigen which had been described in platelet membranes (Sims et al., 1989) . However, in the initial platelet blotting studies, anti-CD59 antibodies identified only a band of apparent molecular mass 18-22 kDa. The detected protein gave an appearance identical with that obtained in this laboratory upon Western blotting of several human nucleated cell types, including neutrophils, lymphocytes, K562 cells, am- The MAC-inhibiting activity of platelet CD59 antigen was confirmed by using the purified protein, which protected GPE from MAC lysis as efficiently as did erythrocyte CD59 antigen. Regulation by CD59 antigen of the non-lethal stimulatory effects of the MAC, which include the induction of procoagulant platelet responses, are likely to be of more relevance in vivo than protection against lysis (Wiedmer et al., 1986; Sims et al., 1988; Morgan, 1989) .
The specific inhibitory activity of the purified protein was approx. 1500-fold that of the membrane extract from which it was derived. However, the final protein yield represented 0.14 % of the protein in the initial detergent extract, from which it can be calculated that the inhibitory activity had increased at least 2-fold over the purification. It is likely that this anomaly is the result of other factors in the platelet membrane extract which enhance lysis of GPEs in the assays used. Assuming that the yield of CD59 antigen was close to 100 %, the average number of molecules of this antigen per platelet can be calculated to be about 1500. This compares with an estimate for erythrocytes of 25000 molecules per cell (Davies et al., 1989 (Low, 1987; Holguin et al., 1990; Walter et al., 1990) . Paroxysmal nocturnal haemoglobinuria is a clonal disorder of haemopoetic stem cells which results in episodes of haemolysis and thrombosis (Rosse, 1990) . The underlying biochemical abnormality is a failure to form stable GPI anchors. As a result, the products of the abnormal clone express markedly decreased amounts (or none) of GPI-anchored proteins, including the complement-inhibitory proteins decay accelerating factor ('DAF'), HRF/MIP and CD59 antigen. Absence of these inhibitors on erythrocytes renders them highly susceptible to haemolysis by complement. Deficiency of DAF on platelets in paroxysmal nocturnal haemoglobinuria has previously been described (Kinoshita et al., 1985) , and this, together with the demonstration of GPI anchoring reported here, make it likely that paroxysmal-nocturnal-haemoglobinuria platelets are also deficient in CD59 antigen. 
